|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SRPRB |
Gene summary for SRPRB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SRPRB | Gene ID | 58477 |
| Gene name | SRP receptor subunit beta | |
| Gene Alias | APMCF1 | |
| Cytomap | 3q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006605 | UniProtAcc | Q549N5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 58477 | SRPRB | LZE2T | Human | Esophagus | ESCC | 5.48e-06 | 1.41e+00 | 0.082 |
| 58477 | SRPRB | LZE3D | Human | Esophagus | HGIN | 9.57e-03 | 2.66e-01 | 0.0668 |
| 58477 | SRPRB | LZE4T | Human | Esophagus | ESCC | 8.61e-18 | 5.38e-01 | 0.0811 |
| 58477 | SRPRB | LZE5T | Human | Esophagus | ESCC | 2.63e-05 | 2.95e-01 | 0.0514 |
| 58477 | SRPRB | LZE7T | Human | Esophagus | ESCC | 1.80e-04 | 4.00e-01 | 0.0667 |
| 58477 | SRPRB | LZE8T | Human | Esophagus | ESCC | 5.59e-07 | 2.69e-01 | 0.067 |
| 58477 | SRPRB | LZE20T | Human | Esophagus | ESCC | 6.18e-09 | 4.69e-01 | 0.0662 |
| 58477 | SRPRB | LZE22T | Human | Esophagus | ESCC | 2.09e-05 | 2.95e-01 | 0.068 |
| 58477 | SRPRB | LZE24T | Human | Esophagus | ESCC | 3.77e-22 | 4.14e-01 | 0.0596 |
| 58477 | SRPRB | P1T-E | Human | Esophagus | ESCC | 4.00e-11 | 3.36e-01 | 0.0875 |
| 58477 | SRPRB | P2T-E | Human | Esophagus | ESCC | 2.53e-52 | 1.28e+00 | 0.1177 |
| 58477 | SRPRB | P4T-E | Human | Esophagus | ESCC | 2.90e-46 | 1.35e+00 | 0.1323 |
| 58477 | SRPRB | P5T-E | Human | Esophagus | ESCC | 6.46e-20 | 6.31e-01 | 0.1327 |
| 58477 | SRPRB | P8T-E | Human | Esophagus | ESCC | 5.30e-22 | 6.61e-01 | 0.0889 |
| 58477 | SRPRB | P9T-E | Human | Esophagus | ESCC | 4.26e-24 | 7.73e-01 | 0.1131 |
| 58477 | SRPRB | P10T-E | Human | Esophagus | ESCC | 8.56e-62 | 1.33e+00 | 0.116 |
| 58477 | SRPRB | P11T-E | Human | Esophagus | ESCC | 1.01e-15 | 7.10e-01 | 0.1426 |
| 58477 | SRPRB | P12T-E | Human | Esophagus | ESCC | 1.52e-22 | 5.36e-01 | 0.1122 |
| 58477 | SRPRB | P15T-E | Human | Esophagus | ESCC | 2.49e-44 | 1.05e+00 | 0.1149 |
| 58477 | SRPRB | P16T-E | Human | Esophagus | ESCC | 3.05e-45 | 1.06e+00 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:007097218 | Esophagus | ESCC | protein localization to endoplasmic reticulum | 52/8552 | 74/18723 | 1.58e-05 | 1.42e-04 | 52 |
| GO:007259915 | Esophagus | ESCC | establishment of protein localization to endoplasmic reticulum | 31/8552 | 46/18723 | 2.42e-03 | 1.06e-02 | 31 |
| GO:004504715 | Esophagus | ESCC | protein targeting to ER | 28/8552 | 42/18723 | 4.90e-03 | 1.89e-02 | 28 |
| GO:007259412 | Liver | Cirrhotic | establishment of protein localization to organelle | 189/4634 | 422/18723 | 1.01e-19 | 2.45e-17 | 189 |
| GO:00066057 | Liver | Cirrhotic | protein targeting | 148/4634 | 314/18723 | 3.86e-18 | 6.20e-16 | 148 |
| GO:00709724 | Liver | Cirrhotic | protein localization to endoplasmic reticulum | 45/4634 | 74/18723 | 4.79e-11 | 2.73e-09 | 45 |
| GO:00725994 | Liver | Cirrhotic | establishment of protein localization to endoplasmic reticulum | 26/4634 | 46/18723 | 4.14e-06 | 6.94e-05 | 26 |
| GO:00450474 | Liver | Cirrhotic | protein targeting to ER | 24/4634 | 42/18723 | 7.49e-06 | 1.15e-04 | 24 |
| GO:007259422 | Liver | HCC | establishment of protein localization to organelle | 299/7958 | 422/18723 | 1.06e-32 | 6.10e-30 | 299 |
| GO:000660512 | Liver | HCC | protein targeting | 219/7958 | 314/18723 | 7.74e-23 | 1.49e-20 | 219 |
| GO:007097212 | Liver | HCC | protein localization to endoplasmic reticulum | 54/7958 | 74/18723 | 1.01e-07 | 1.98e-06 | 54 |
| GO:007259911 | Liver | HCC | establishment of protein localization to endoplasmic reticulum | 34/7958 | 46/18723 | 1.53e-05 | 1.67e-04 | 34 |
| GO:004504711 | Liver | HCC | protein targeting to ER | 30/7958 | 42/18723 | 1.40e-04 | 1.13e-03 | 30 |
| GO:007259418 | Oral cavity | OSCC | establishment of protein localization to organelle | 284/7305 | 422/18723 | 1.50e-32 | 1.35e-29 | 284 |
| GO:000660520 | Oral cavity | OSCC | protein targeting | 204/7305 | 314/18723 | 6.78e-21 | 1.13e-18 | 204 |
| GO:00709729 | Oral cavity | OSCC | protein localization to endoplasmic reticulum | 50/7305 | 74/18723 | 6.03e-07 | 8.64e-06 | 50 |
| GO:00725998 | Oral cavity | OSCC | establishment of protein localization to endoplasmic reticulum | 30/7305 | 46/18723 | 2.86e-04 | 1.80e-03 | 30 |
| GO:00450477 | Oral cavity | OSCC | protein targeting to ER | 27/7305 | 42/18723 | 8.00e-04 | 4.29e-03 | 27 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0306026 | Esophagus | ESCC | Protein export | 22/4205 | 23/8465 | 2.43e-06 | 1.43e-05 | 7.32e-06 | 22 |
| hsa0306036 | Esophagus | ESCC | Protein export | 22/4205 | 23/8465 | 2.43e-06 | 1.43e-05 | 7.32e-06 | 22 |
| hsa030608 | Liver | Cirrhotic | Protein export | 20/2530 | 23/8465 | 2.00e-08 | 3.51e-07 | 2.17e-07 | 20 |
| hsa0306011 | Liver | Cirrhotic | Protein export | 20/2530 | 23/8465 | 2.00e-08 | 3.51e-07 | 2.17e-07 | 20 |
| hsa0306025 | Oral cavity | LP | Protein export | 21/2418 | 23/8465 | 4.72e-10 | 8.28e-09 | 5.34e-09 | 21 |
| hsa0306035 | Oral cavity | LP | Protein export | 21/2418 | 23/8465 | 4.72e-10 | 8.28e-09 | 5.34e-09 | 21 |
| hsa0306016 | Prostate | BPH | Protein export | 18/1718 | 23/8465 | 3.72e-09 | 5.11e-08 | 3.16e-08 | 18 |
| hsa0306017 | Prostate | BPH | Protein export | 18/1718 | 23/8465 | 3.72e-09 | 5.11e-08 | 3.16e-08 | 18 |
| hsa0306024 | Prostate | Tumor | Protein export | 18/1791 | 23/8465 | 7.50e-09 | 1.03e-07 | 6.42e-08 | 18 |
| hsa0306034 | Prostate | Tumor | Protein export | 18/1791 | 23/8465 | 7.50e-09 | 1.03e-07 | 6.42e-08 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SRPRB | SNV | Missense_Mutation | rs780491153 | c.124G>A | p.Val42Met | p.V42M | Q9Y5M8 | protein_coding | deleterious(0.01) | benign(0.17) | TCGA-A2-A1FV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
| SRPRB | SNV | Missense_Mutation | c.384C>A | p.Phe128Leu | p.F128L | Q9Y5M8 | protein_coding | tolerated(0.08) | benign(0.01) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SRPRB | SNV | Missense_Mutation | c.243T>A | p.Phe81Leu | p.F81L | Q9Y5M8 | protein_coding | deleterious(0) | possibly_damaging(0.834) | TCGA-JW-A852-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| SRPRB | SNV | Missense_Mutation | novel | c.231N>C | p.Lys77Asn | p.K77N | Q9Y5M8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SRPRB | SNV | Missense_Mutation | rs141286101 | c.623N>A | p.Arg208His | p.R208H | Q9Y5M8 | protein_coding | deleterious(0.01) | benign(0.065) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SRPRB | SNV | Missense_Mutation | c.668C>A | p.Ala223Asp | p.A223D | Q9Y5M8 | protein_coding | deleterious(0.01) | benign(0.271) | TCGA-AG-4007-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| SRPRB | SNV | Missense_Mutation | novel | c.464N>G | p.Val155Gly | p.V155G | Q9Y5M8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-A015-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| SRPRB | SNV | Missense_Mutation | novel | c.16N>A | p.Ser6Thr | p.S6T | Q9Y5M8 | protein_coding | tolerated_low_confidence(0.38) | benign(0) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SRPRB | SNV | Missense_Mutation | novel | c.341N>A | p.Thr114Asn | p.T114N | Q9Y5M8 | protein_coding | tolerated(0.18) | benign(0.147) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SRPRB | SNV | Missense_Mutation | novel | c.413N>A | p.Ala138Asp | p.A138D | Q9Y5M8 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 58477 | SRPRB | NA | ethanol | ALCOHOL | 31002879 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |